Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
But the shares are sold to new investors at 20p. So how likely that they get to £1,13p in 180 days?
Not sure if I understand. New shareholders pay 20p a share and old shareholders have a right to buy 1 share for each 440 held at the price of 30p. 50% higher than new investors? If the price never goes above 30p warrants are worthless!
Joanne not the inhalation specialist.
Dr Anne Brindley, Chief Executive Officer
– Over 30 years in Big Pharma and Biotech (GSK, AZ, J&J/Respivert, Skyepharma,
Advent/AuroScience) with extensive expertise in respiratory and oncology R&D,
and business development including in / out-licensing and M&A including
company sale.
– Key role in successful inhaled products – Symbicort® (AZ) and flutiform®
(Skyepharma).
– Extensive expertise in R&D in respiratory and oncology therapy areas - for
innovator and generic products
– Former CEO Advent Pharmaceuticals Pty Ltd/ AuroScience Pty Ltd (Australia)
with successful sale of the business
Dr Joanne Holland, Chief Scientific Officer
– Over 18 years’ experience in R&D, IP & commercial roles within the
pharmaceutical Industry.
– Expert in pharmaceutical solid forms, co-crystals, process R&D and drug
reprofiling (Millennium, Stylacats). Leader in novel physical forms / cocrystal
technology
NXP001 Oxilio News would be welcome. Do they have to give details though?
NXP002 may well take upto 18 months before news, hence the new chairmans statement. Again from the Allenby report:
NFX DCF valuation of 9p per share post funding
Our DCF valuation of NFX includes only NXP002 at this stage. Using a 13% WACC gives a
risk adjusted valuation of £52.8m, equivalent to 9 pence per share, and this assumes that
a Phase I ready package for NXP002 is in place. Subject to financing, NFX anticipates that
this milestone could be achieved within the next 18 months, but with multiple
opportunities for licensing NXP002 prior to this.
I don't know why people expect news.
From Allenby Capital Report in Mar 2021
NFX will
apply its extensive expertise in inhaled therapies to advance the programme to the next
inflection point in six-to nine months’ time and, if the planned preclinical studies support
its earlier promise, seek licensing partners thereafter.
Of course it matters where the price is! The 15% dilution comes at 20% discount to the reigning price and as everyone knows it will be cheaper at the point of raise there is constant selling!
We were told there was no need to raise. Every other raise has been an insult to existing shareholders because each time it's a lower price. This should have become self funding by growing value and selling a proportion of most productive holding.
When the company intimated it foresaw no need to raise money this year and let the resolution to issue new shares go confidence was finally restored. They only need one exit to fund everything else.
But no! A special meeting to give permission to raise 15% when ever they want, and we all know they raise whatever the price has slipped to. Why would anyone hold? Wait for the raise and buy when the price drops back towards the 20% kick in the teeth for the unfortunates in this pass the parcel. There's big value here but everyone knows there will be a chance to buy back in cheaper.
Of course a serious buyer could also be picking up all the big sells as well. What better time to build a stake when all the owners from the 2p fund raise are flogging for a quick profit.
Simon Thompson in Investors Chronicle today reiterates his 170p target price.
They were at Bath University together in the 80s
From RNS Tue, 29th Sep 2020 07:00
Business performance impacted by Google manual ranking penalty and Covid-19 - approximately $2 million per month impact from late March
Will submit specific rebuilt sites for reconsideration by Google, where appropriate, by the end of the fourth quarter of 2020.
Not impressed by the time taken fiddling around and no update. I think the new management like the idea of buying things and pseudo science business waffle but this should have been sorted.
Does Chris Blackwell know Anne Brindley from Bath University? They were both there from 1984 to 1987. Might not need to pay a finders fee etc.